PF-00562271 [Target: FAK] PF-00562271, an orally available small molecule, has been shown to inhibit focal adhesion kinase (FAK) signaling. FAK is a signal transducer for integrins, and it coordinates with growth factor receptors in cancer cells. FAK expression is correlated with tumor invasion and with the migration, proliferation, and survival of tumor cells.
PF-00562271 is currently in phase 1 trials of several solid tumors.1
PF-3732010 [Target: P-cadherin] PF-3732010 is an injectable, fully human IgG1 monoclonal antibody that antagonizes the function of P-cadherin. Based on preclinical work, PF-3732010 is being investigated to determine direct effects on tumor cell adhesion and intracellular signaling, as well as in directing immune effector function against P-cadherin-expressing tumor cells. PF-3732010 will be studied as both a single agent and in combination with standard of care in a variety of solid tumors.1
PF-00299804, CP-751,871, PF-00562271, and PF-3732010 are investigational compounds.
Information in the Oncology Investigational Pipeline relates to therapies currently being researched.